Abstract 251P
Background
Approximately 850 women die each year of advanced breast cancer (aBC) in Finland, however this population is poorly characterized. The aim of this study was to identify aBC patients and characterize them in terms of tumour subtypes and survival outcomes, using real-world data from a regional Finnish cohort.
Methods
The study was conducted analyzing data from the District of Southwest Finland (Auria Biobank) – covering 20% of the Finnish population. Patients diagnosed with aBC between 2004-2013 were identified through text mining algorithms, and followed until the end of 2016. BC tumour markers included hormone receptors (HR), human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki67 to allow for detailed subgroup analyses. Data is presented by summary descriptive statistics, with overall survival (OS) calculated using the Kaplan-Meier method. Clinical pathology and survival data were collected from Auria Biobank and electronic medical records.
Results
Of 444 aBC patients identified, 64.9% displayed an HR+/HER2- subtype. Median OS was 20.1 months (95 % CI: 17.7-23.4) for the entire aBC population, with 22.6 months (95% CI: 19.4-25.6) for HR+/HER2-, 23.1 months (95% CI: 12.7-37.7) for HER2+, and 5.5 months (95% CI: 3.6-15.2) for the triple negative BC (TNBC) subgroups. Detailed baseline and efficacy data will be further described. The aggressive disease course in TNBC was also reflected in the frequency of patient with short (<2 years) disease-free interval (DFI, defined as time from early BC diagnosis to aBC diagnosis). For DFI <2 years, the corresponding numbers were 84.0% for TNBC patients, 50.7% for HR+/HER2- and 65.5% for HER2+ (HR+/-), respectively.
Conclusions
To our knowledge, this is the first retrospective study reporting OS and DFI of aBC subgroups in Finland. The data is consistent with the know data for TNBC, the vast majority of TNBC patients recur within the first two years from primary BC diagnosis; in contrast to the other patient subgroups. In addition, HR+/HER2- and HER2+ patients have similar OS outcomes, while TNBC patients have the shortest OS. These findings probably reflect the differences in available treatments for the above-mentioned subgroups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis.
Funding
Novartis.
Disclosure
K. Heinolainen: Full/Part-time employment: Novartis. S. Saarinen: Full/Part-time employment: Novartis. P. Carlqvist: Full/Part-time employment: Novartis. J. Mandelin: Full/Part-time employment: Novartis. M. Utriainen: Advisory/Consultancy: Novartis. S. Vertuani: Full/Part-time employment: Novartis. B. Holm: Full/Part-time employment: Novartis. All other authors have declared no conflicts of interest.